What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Alzheimer's disease
- Disease
His primary areas of study are Dementia, Alzheimer's disease, Internal medicine, Psychiatry and Disease.
The concepts of his Dementia study are interwoven with issues in Clinical trial, Cognition, Data collection and Data set.
His research in Alzheimer's disease intersects with topics in Positron emission tomography, Nuclear medicine, Gerontology and Degenerative disease.
The various areas that he examines in his Internal medicine study include Placebo and Surgery.
His Psychiatry research focuses on Clinical psychology and how it relates to Psychiatric status rating scales.
His work deals with themes such as Genetics, Physical medicine and rehabilitation and Activities of daily living, which intersect with Disease.
His most cited work include:
- The Global Deterioration Scale for assessment of primary degenerative dementia. (3702 citations)
- Memantine in Moderate-to-Severe Alzheimer's Disease (1517 citations)
- Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment (1443 citations)
What are the main themes of his work throughout his whole career to date?
Steven H. Ferris focuses on Disease, Dementia, Alzheimer's disease, Cognition and Psychiatry.
His research in Disease tackles topics such as Clinical trial which are related to areas like Physical therapy.
His research investigates the connection between Dementia and topics such as Gerontology that intersect with problems in Longitudinal study.
His research on Alzheimer's disease concerns the broader Internal medicine.
The Internal medicine study which covers Placebo that intersects with Adverse effect.
The study incorporates disciplines such as Developmental psychology, Physical medicine and rehabilitation, Audiology and Cognitive decline in addition to Cognition.
He most often published in these fields:
- Disease (37.12%)
- Dementia (30.75%)
- Alzheimer's disease (27.70%)
What were the highlights of his more recent work (between 2009-2019)?
- Disease (37.12%)
- Cognition (25.48%)
- Alzheimer's disease (27.70%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Disease, Cognition, Alzheimer's disease, Internal medicine and Dementia.
His Disease research is multidisciplinary, relying on both Psychiatry, Clinical trial, Gerontology and Rating scale.
His Cognition research includes themes of Rivastigmine, Activities of daily living, Physical medicine and rehabilitation and Clinical psychology.
His studies deal with areas such as Clinical Global Impression, White matter, Myelin and Genetics as well as Alzheimer's disease.
His research integrates issues of Placebo and Oncology in his study of Internal medicine.
His Dementia research is multidisciplinary, incorporating elements of Interactive kiosk, Clinical endpoint and Episodic memory.
Between 2009 and 2019, his most popular works were:
- Common variants at MS4A4/MS4A6E , CD2AP , CD33 and EPHA1 are associated with late-onset Alzheimer's disease (1385 citations)
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease (1163 citations)
- Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (429 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cognition
Steven H. Ferris spends much of his time researching Alzheimer's disease, Disease, Genetics, Cognition and Gerontology.
His biological study spans a wide range of topics, including Progressive supranuclear palsy, Myelin, Dementia and White matter.
His study of Clinical Dementia Rating is a part of Dementia.
His Disease research integrates issues from Psychiatry, Pharmacotherapy, Clinical trial and Rating scale.
As part of one scientific family, Steven H. Ferris deals mainly with the area of Clinical trial, narrowing it down to issues related to the Cohort, and often Placebo.
Steven H. Ferris has included themes like Rivastigmine, Galantamine and Cognitive decline in his Cognition study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
